Welcome to our dedicated page for EyePoint Pharmaceuticals news (Ticker: EYPT), a resource for investors and traders seeking the latest updates and insights on EyePoint Pharmaceuticals stock.
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts. The company is committed to developing and commercializing ophthalmic products aimed at treating serious retinal diseases. EyePoint leverages its proprietary Durasert® technology, a sustained intraocular drug delivery system, to create treatments that can provide continuous therapeutic effects for extended periods.
EyePoint Pharmaceuticals has made significant strides in the field of retinal disease treatments. Its lead product candidate, DURAVYU™ (previously known as EYP-1901), is an investigational treatment for VEGF-mediated retinal diseases. This product combines vorolanib, a selective tyrosine kinase inhibitor, with the Durasert® technology to offer sustained delivery and improved patient outcomes. DURAVYU™ is currently undergoing clinical trials for conditions such as wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy (NPDR).
The company also has several other promising candidates in its pipeline, including EYP-2301, a TIE-2 agonist, and razuprotafib, formulated with Durasert® technology to potentially enhance treatment outcomes for serious retinal diseases.
EyePoint’s innovative approach extends beyond product development to strategic partnerships and collaborations. The company has secured exclusive licenses for vorolanib from Equinox Sciences for all ophthalmic uses outside of China, Macao, Hong Kong, and Taiwan. Additionally, EyePoint has FDA-approved products such as RETISERT® and YUTIQ® that are based on its proprietary drug delivery technology.
Financially, EyePoint Pharmaceuticals has shown a solid performance with total net revenue of $46.0 million for the year ended December 31, 2023, compared to $41.4 million for the previous year. This growth is driven primarily by revenues from royalties and collaborations. The company has also strengthened its financial position with $331.1 million in cash, cash equivalents, and marketable securities as of December 31, 2023.
EyePoint is dedicated to driving innovation in ophthalmology and improving the quality of life for patients with serious eye conditions. With a focus on advancing its robust pipeline through clinical development, EyePoint Pharmaceuticals continues to make headway in addressing unmet medical needs in retinal diseases.
EyePoint Pharmaceuticals has dosed the first patient in its Phase 3 LUGANO clinical trial of DURAVYU™ for wet age-related macular degeneration (wet AMD). The trial, along with the upcoming LUCIA study, will evaluate DURAVYU's efficacy against aflibercept in approximately 400 patients globally. DURAVYU is administered every six months, compared to current treatments requiring frequent injections. The primary endpoint is measuring change in best corrected visual acuity at weeks 52 and 56. With over 150 clinical sites committed, the company expects topline data in 2026. The trials include both treatment-naïve and experienced patients, reflecting real-world populations.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has announced the granting of non-statutory stock options to four new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan. These grants, approved by the Compensation Committee, are in accordance with NASDAQ Listing Rule 5635(c)(4). The stock options, totaling 69,000 shares of EyePoint Pharmaceuticals common stock, were granted on October 15, 2024, with an exercise price of $9.88 per share.
The options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and the remainder vesting in equal monthly installments over the following three years. Vesting is subject to continued service with the company.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has granted non-statutory stock options to two new employees as inducement awards outside its 2023 Long-Term Incentive Plan. The grants, approved by the Compensation Committee, comply with NASDAQ Listing Rule 5635(c)(4). Key details include:
- 43,000 shares of common stock options granted
- Grant date: September 13, 2024
- Exercise price: $9.10 per share (closing price on grant date)
- Ten-year term
- Vesting over four years: 25% after one year, remainder in monthly installments over three years
- Vesting contingent on continued employment
These inducement awards aim to attract and retain talent in EyePoint's mission to develop therapeutics for serious retinal diseases.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has appointed Fred Hassan, a distinguished industry leader, to its Board of Directors. This strategic move comes as the company prepares for the Phase 3 LUGANO trial of DURAVYU™ in wet age-related macular degeneration (AMD) and future commercialization. Hassan, former CEO of three global pharmaceutical companies, brings extensive biopharmaceutical experience to EyePoint.
Simultaneously, Anthony P. Adamis, M.D. and David Guyer, M.D. have resigned from the Board due to their transition to full-time roles at Merck & Co. The company acknowledges their contributions in shaping EyePoint's product development pipeline and clinical strategies.
EyePoint Pharmaceuticals (NASDAQ: EYPT), a company focused on developing innovative therapeutics for serious retinal diseases, has announced its participation in several upcoming investor conferences. These include:
- Morgan Stanley Annual Global Healthcare Conference (September 4, 2024)
- Baird Global Healthcare Conference (September 10, 2024)
- Cantor Global Healthcare Conference (September 18, 2024)
- UBS Virtual Ophthalmology Day (October 2, 2024)
The company will engage in various formats, including 1x1 investor meetings and fireside chats. Live webcasts and archived replays of the presentations will be available on the company's website.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has granted non-statutory stock options to nine new employees as inducement awards outside its 2023 Long-Term Incentive Plan. The company, focused on developing therapeutics for serious retinal diseases, issued options to purchase up to 106,600 shares of common stock on August 15, 2024. These grants, approved by the Compensation Committee, have an exercise price of $8.20 per share, matching the closing price on the grant date. The options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and the remainder in equal monthly installments over the following three years, subject to continued employment.
EyePoint Pharmaceuticals (NASDAQ: EYPT), a company focused on developing innovative therapeutics for serious retinal diseases, has announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference. The event will take place on Thursday, August 15th, 2024.
Dr. Jay S. Duker, President and CEO of EyePoint, will present a Company Overview available on-demand from 7:00 a.m. ET. Additionally, he will participate in a panel discussion on 'The Evolving Therapeutic Landscape of AMD' at 9:00 a.m. ET.
Investors can access live webcasts and archived replays of both presentations through the Investors section of EyePoint's website. The replay will remain available for 90 days after the event.
EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q2 2024 financial results and corporate updates. Key highlights include:
1. Phase 3 LUGANO trial of DURAVYU™ for wet AMD on track for first patient dosing in 2024.
2. Positive 12-month data from Phase 2 DAVIO 2 trial of DURAVYU in wet AMD.
3. Phase 2 VERONA trial of DURAVYU in DME fully enrolled; topline data expected Q1 2025.
4. $280.2 million cash and investments as of June 30, 2024.
5. Q2 2024 total net revenue: $9.5 million.
6. Net loss: $30.8 million, or ($0.58) per share.
7. Cash runway through Phase 3 wet AMD topline data for DURAVYU in 2026.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has granted non-statutory stock options to nine new employees as inducement awards outside its 2023 Long-Term Incentive Plan. The company, focused on developing therapeutics for serious retinal diseases, issued options to purchase up to 57,700 shares of common stock on July 15, 2024. These grants, approved by the Compensation Committee, have an exercise price of $10.54 per share, matching the closing price on the grant date. The options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and the remainder in equal monthly installments over the following three years, subject to continued employment.
EyePoint Pharmaceuticals will highlight the clinical and regulatory progress of DURAVYU™ (vorolanib intravitreal insert) and pipeline innovations at their R&D Day on June 26, 2024. Key updates include the Phase 3 trial design for LUGANO and LUCIA pivotal trials in wet AMD scheduled for 2H 2024 following a positive FDA meeting, and positive twelve-month safety and efficacy data from the Phase 2 DAVIO 2 trial. DURAVYU shows promise as a six-month maintenance therapy with no serious adverse events reported. The VERONA Phase 2 trial in diabetic macular edema has completed enrollment. EyePoint aims to advance DURAVYU as a significant treatment for VEGF-mediated retinal diseases.
FAQ
What is the current stock price of EyePoint Pharmaceuticals (EYPT)?
What is the market cap of EyePoint Pharmaceuticals (EYPT)?
What does EyePoint Pharmaceuticals, Inc. (EYPT) specialize in?
What is DURAVYU™?
Where is EyePoint Pharmaceuticals headquartered?
What are the key products in EyePoint's pipeline?
How did EyePoint Pharmaceuticals perform financially in 2023?
What is the Durasert® technology?
Has EyePoint Pharmaceuticals received FDA approval for any products?
What are the geographical operational footprints of EyePoint Pharmaceuticals?
What is EyePoint's strategy for future growth?
How does EyePoint Pharmaceuticals generate revenue?
